Kamban Hirasen to Female
This is a "connection" page, showing publications Kamban Hirasen has written about Female.
Connection Strength
0,193
-
High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa. PLoS One. 2018; 13(10):e0205463.
Score: 0,060
-
Costs and outcomes of routine HIV oral pre-exposure prophylaxis implementation across different service delivery models and key populations in South Africa: a retrospective cohort study. Lancet HIV. 2025 Feb; 12(2):e130-e142.
Score: 0,023
-
Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis. PLoS One. 2024; 19(10):e0309034.
Score: 0,023
-
Cost outcome analysis of decentralized care for drug-resistant tuberculosis in Johannesburg, South Africa. PLoS One. 2019; 14(6):e0217820.
Score: 0,016
-
Adverse Drug Reactions Among Patients Initiating Second-Line Antiretroviral Therapy in South Africa. Drug Saf. 2018 12; 41(12):1343-1353.
Score: 0,015
-
Low prevalence of depressive symptoms among stable patients on antiretroviral therapy in Johannesburg, South Africa. PLoS One. 2018; 13(9):e0203797.
Score: 0,015
-
Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa. AIDS Res Ther. 2018 04 10; 15(1):10.
Score: 0,015
-
Predicting the Need for Third-Line Antiretroviral Therapy by Identifying Patients at High Risk for Failing Second-Line Antiretroviral Therapy in South Africa. AIDS Patient Care STDS. 2017 May; 31(5):205-212.
Score: 0,014
-
Early Outcomes Of Decentralized Care for Rifampicin-Resistant Tuberculosis in Johannesburg, South Africa: An Observational Cohort Study. PLoS One. 2016; 11(11):e0164974.
Score: 0,013